JPH045226A - Surface-modifiable liposomes and methods for producing surface-modified liposomes - Google Patents
Surface-modifiable liposomes and methods for producing surface-modified liposomesInfo
- Publication number
- JPH045226A JPH045226A JP2104670A JP10467090A JPH045226A JP H045226 A JPH045226 A JP H045226A JP 2104670 A JP2104670 A JP 2104670A JP 10467090 A JP10467090 A JP 10467090A JP H045226 A JPH045226 A JP H045226A
- Authority
- JP
- Japan
- Prior art keywords
- liposomes
- liposome
- modifiable
- general formula
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims description 84
- 238000000034 method Methods 0.000 title description 52
- 239000000758 substrate Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 125000001165 hydrophobic group Chemical group 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 125000000962 organic group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- -1 amide compounds Chemical class 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000010640 amide synthesis reaction Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- WZMNQOYCHMGCSS-UHFFFAOYSA-N n,n-dimethyl-1-oxidopyridin-1-ium-4-amine Chemical compound CN(C)C1=CC=[N+]([O-])C=C1 WZMNQOYCHMGCSS-UHFFFAOYSA-N 0.000 description 2
- WZXIZIMRENKAAF-LSLCXQBJSA-N n-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O WZXIZIMRENKAAF-LSLCXQBJSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- OGEDOBZILFEBDN-UHFFFAOYSA-N benzylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.NCC1=CC=CC=C1 OGEDOBZILFEBDN-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
(産業上の利用分野]
本発明に、薬物運搬体、免疫分析試薬などに用いられる
表面修飾可能なリポソームと表面修飾されたリポソーム
の製造方法に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to a surface-modifiable liposome used as a drug carrier, an immunoassay reagent, etc., and a method for producing the surface-modified liposome.
(従来の技術)
近年、医学・薬学分野において正常な細胞や組織には影
響を与えず、患部となついてる細胞や組織に選択的に薬
物全運搬し、薬効を発現させる手法(ドラッグデリバリ
−システム、DDS )が検討されている。(Conventional technology) In recent years, in the medical and pharmaceutical fields, a method (drug delivery system) has been developed to selectively deliver all drugs to cells and tissues that are attached to the affected area without affecting normal cells and tissues. , DDS) are being considered.
これを達成する方法として、リポソームに親水性あるい
は脂溶性の薬効を担持させ、表面にたんばく質、抗原、
抗体、糖(多糖金倉む)等を固定化した表面修飾リポソ
ームが検討されている。To achieve this, liposomes are loaded with hydrophilic or lipophilic drugs, and proteins, antigens,
Surface-modified liposomes with immobilized antibodies, sugars (polysaccharide Kanakuramu), etc. are being investigated.
〔キャンサーリサーチ(Cancer、Res、)第≠
3巻、13λ1頁、lり13年、同誌、見!、亨ダ7/
(/り17)、リポソーム リサ・−チ(Liposo
me Res、)、 @/巻、is頁(lりrt−tり
年)〕
一万、リポソームは不安定であり、特に生体内投与にお
ける網内皮糸に存在する貧食細胞による貧食あるいは、
血中からの消失が非常に速いことが問題である。これら
の解決法として、特開昭6J−J/37コ弘号には多糖
誘導体によってリポソーム表面を修飾する方法が開示さ
れている。[Cancer Research (Cancer, Res,) No. ≠
Volume 3, page 13λ1, 13 years ago, same magazine, see! , Toru Da 7/
(/ri17), Liposome Lisa-chi (Liposo
10,000, liposomes are unstable and are particularly susceptible to phagocytosis by phagocytic cells present in reticuloendothelial threads during in vivo administration, or
The problem is that it disappears from the blood very quickly. As a solution to these problems, Japanese Patent Application Laid-Open No. 6J-J/37 discloses a method of modifying the surface of liposomes with a polysaccharide derivative.
さらに臨床検査や免疫学の分野において、生理活性物質
、免疫活性物質(抗体、抗原を含む]等をリポソーム表
面に固定化した表面修飾リポソームを用いる種々の分析
法が開示されている〔特開昭47−2101!r号、特
開昭47−1≦26J号、特開昭40−/31≠4を号
〕。Furthermore, in the fields of clinical testing and immunology, various analytical methods using surface-modified liposomes in which physiologically active substances, immunologically active substances (including antibodies and antigens), etc. are immobilized on the liposome surface have been disclosed [JP-A-Sho No. 47-2101!r, JP-A No. 47-1≦26J, JP-A No. 40-/31≠4].
リポソームの表面を修飾する方法としては、代表的な方
法として、N−J−(2−ジチオピリジルコプロピオニ
ル ホス7アチジルエタノールアミン(DTP−PE)
にN−スクシンイミジルー3−(λ−ピリジルジチオ)
プロピオネート(8PDP)で活性化したたんば(質等
を結合する方法〔ネイチャー(Nature)、$21
1巻、402頁、/ P10年〕や、架橋剤を用いる方
法(架橋剤としてμN−スクシンイミジルー+ −(p
−マレイミドフェニル)ブチレート(8MPB)、N−
スクシンイミジル−≠−(p−マレイミドフェニル)ア
セテート(8MPA)、N−スクシンイミジル−4’−
(p−マレイミドフェニル)プロピオネート(8MPP
)等が知られている)〔ジャーナル オブ バイオロ
ジカル ケミストリー(J、 Biol、 C
hem、 ン、 @J 7 7 巻、 −214頁
、lりrλ年等〕が挙げられる。A typical method for modifying the surface of liposomes is N-J-(2-dithiopyridylcopropionyl phos-7atidylethanolamine (DTP-PE)).
N-succinimidyl-3-(λ-pyridyldithio)
A method of combining propionate (8PDP) activated tanba (quality, etc.) [Nature, $21
Volume 1, page 402, / P10], the method using a crosslinking agent (μN-succinimidyl + -(p
-maleimidophenyl)butyrate (8MPB), N-
Succinimidyl-≠-(p-maleimidophenyl)acetate (8MPA), N-succinimidyl-4'-
(p-maleimidophenyl)propionate (8MPP
) [Journal of Biological Chemistry (J, Biol, C
Hem, N, @J7, vol. 7, p. -214, 1995, etc.).
リポソーム表面への基質の固定化の他の方法としては、
リポソーム調製時に予め楯脂質等を混合しておき、その
糖を酸化することによりアルデヒド基金生成させこれと
たんばく質等のアミノ基とを反応させシッフ塩基金形成
させる方法〔バイオヒミカ アト バイオフイジヵ ア
クタ(Biochim−Biophys、 Act、)
、第tUO巻、ぶ4頁、/91/年等〕やたんばく質等
に疎水性基を導入して、別途調製したリポソームに組み
込む方法〔バイオ辷ミカ アト バイオフイジヵ アク
タ(Biochjm、Biophys−Acta)。Other methods for immobilizing substrates on the surface of liposomes include
A method in which shield lipids, etc. are mixed in advance during liposome preparation, and the sugars are oxidized to form an aldehyde fund, which is reacted with amino groups such as proteins to form a Schiff salt fund. -Biophys, Act,)
, Vol. tUO, p. 4, /91/) and methods of introducing hydrophobic groups into proteins and incorporating them into separately prepared liposomes [Biochjm, Biophys-Acta]. .
第rix巻、114頁、79!!年等〕がある。Volume rix, page 114, 79! ! year, etc.).
しかしながら、これらの方法は段階数が多く、複雑であ
り、容易にリポソーム表面に基質を固定化し修飾する方
法の確立が本分野において必要性の高い課題となってい
る。However, these methods have many steps and are complicated, and the establishment of a method for easily immobilizing and modifying a substrate on the surface of liposomes is a highly needed issue in this field.
一万、有機合成化学の分野において3−アシルチアゾリ
ジン−コーチオンを用いた、カルボン酸誘導体を還元し
て収率よくアルデヒドを製造する方法〔特開昭74L−
72271、ケミストリーレターズ、(Chem、Le
tt、)、1aa3頁、lり77年〕や、選択的にアミ
ドを製造する方法〔テトラヘトoy レターズ(Te
trahedronLett−)、第21巻、1101
頁、1yto年、ヘテロサイクルズ(Hetero
cycles)、第77巻、!37頁、/りt2年〕お
よびチオエステル金製造する方法〔ジャーナル オプ
ケミカルリサーチ(J、Chem、Re5earch(
S)、/213年、20頁〕が開示されている。しかし
3−アシルチアゾリジン−コーチオンがリポソームの表
面修飾試薬として用いられた例はない。10,000, in the field of organic synthetic chemistry, a method for producing aldehydes in good yield by reducing carboxylic acid derivatives using 3-acylthiazolidine-corchion [JP-A-74L-
72271, Chemistry Letters, (Chem, Le
), p. 1aa3, 1977], and a method for selectively producing amides [Tetrahetoy Letters (Tetrahetoy Letters)].
trahedronLett-), Volume 21, 1101
Page, 1yto, Heterocycles
cycles), Volume 77,! 37 pages, /2 years] and method for producing thioester gold [Journal Op.
Chemical Research (J, Chem, Re5search (
S), /213, p. 20] is disclosed. However, there is no example of 3-acylthiazolidine-corchion being used as a surface modification reagent for liposomes.
また、高分子化学の分野において、コ(3H)−ベンゾ
オキサシロン、2(JH)−ベンゾチアゾロンを脱離基
にもち、化学選択的にアミドを形成する活性化剤〔有機
合成化生協会誌、第≠を巻。In addition, in the field of polymer chemistry, activators that have co(3H)-benzoxacilone and 2(JH)-benzothiazolone as leaving groups and chemoselectively form amides [Journal of the Society for Organic Synthesis, Vol. Roll ≠.
ハリ頁、/りtり年、ブリティン オブ サケミカル
ンナイアテイ シャラミン Bull。Hari page, / year, Bulletin of Salmony
Nnaiatei Shalamin Bull.
Chem−8oc、 Jpn、、第zt巻、32り1
頁、/ f I 7年、マクロモレキュルズMacro
molecules 、第11巻、2313頁1ytz
年〕が開示されている。Chem-8oc, Jpn, vol. zt, 32ri 1
Page, /f I 7th year, Macro Molecules Macro
molecules, vol. 11, p. 2313 1ytz
] has been disclosed.
しかし、これらの脱離基ヲ有したアミド化合物がリポソ
ームの表面修飾試薬として用いられた例にない。However, there are no examples of amide compounds having these leaving groups being used as surface modification reagents for liposomes.
(発明が解決しようとする課題〉
従って1本発明の目的に従来法の問題点を解決し、リポ
ソーム表面にはプチド(アミノI12を含tr )、た
んば(質(抗原、抗体を含む)、糖(多糖を含む)等の
種々の基質を固定化した表面修飾リポソームを容易に製
造する方法を提供すること、および穫々の基質を固定化
した表面修飾リポソームを提供することである。(Problems to be Solved by the Invention) Therefore, one purpose of the present invention is to solve the problems of the conventional method, and to coat the surface of the liposome with peptide (containing amino I12), protein (containing antigen and antibody), The object of the present invention is to provide a method for easily producing surface-modified liposomes on which various substrates such as sugars (including polysaccharides) are immobilized, and to provide surface-modified liposomes on which various substrates are immobilized.
(課題を解決するための手段)
本発明の目的に、
(1)下記、一般式CI)で示される化合物とリポソー
ム形成可能な脂質から構成されること′fI:特徴とす
る表面修飾可能なリポソーム
(R1に疎水性基を示す、R,2、R3は有機基(Ht
−含む)を示す@ ”2 s ”3に互いに連結して環
又は二重結合を形成してもよい。X、Yに酸素原子また
に硫黄原子を示す;
(21(1)記載の表面修飾可能7r リポソームとア
ミノ基及び/又にチオール基金有する基質を混合するこ
とを特徴とする表面修飾されたリポソームの製造方法;
(3) (1)記載の一般式1”I)で表される化合
物の少なくとも7株とアミノ基及び/又にチオール基t
−Wする基質を結合させて得られた化合物とリポソーム
形成可能な脂質を混合することを特徴とする表面修飾さ
れたリポソームの製造方法;によって連成された。(Means for Solving the Problems) For the purpose of the present invention, (1) be composed of a compound represented by the following general formula CI) and a lipid capable of forming liposomes'fI: characterized surface-modifiable liposomes; (R1 represents a hydrophobic group, R, 2, and R3 are organic groups (Ht
- may be linked to each other to form a ring or a double bond. An oxygen atom or a sulfur atom is shown in X and Y; Production method; (3) At least seven strains of the compound represented by the general formula 1"I) described in (1) and an amino group and/or a thiol group t
- A method for producing surface-modified liposomes, which is characterized by mixing a compound obtained by binding a substrate that binds to a liposome-forming lipid with a lipid capable of forming liposomes.
本発明に言いかえれば、リボンームニ分子膜中に一般式
CI)で示される長鎖活性アミド、を埋め込んだリポソ
ームを用いて、アミノ基あるいにチオール基を有した基
質をリポソーム表面に固定化すること、および一般式C
I)に示される長鎖活性アミドとアミノ基あるいにチオ
ール基t−Wした基質を反応させ長鎖基tVした基質誘
導体とし、これf リポソーム形成脂質と混合してリポ
ソームを形成することを骨子とするものである。In other words, in the present invention, a substrate having an amino group or a thiol group is immobilized on the surface of the liposome using a liposome in which a long-chain active amide represented by the general formula CI) is embedded in the ribbon membrane molecular membrane. and general formula C
The main idea is to react the long-chain active amide shown in I) with a substrate containing an amino group or a thiol group to form a substrate derivative containing a long-chain group, and then mix this with a liposome-forming lipid to form a liposome. That is.
本発明の表面修飾リポソームの形成法について説明する
。A method for forming surface-modified liposomes of the present invention will be explained.
第一の方法はリポソーム構成素材に一般式〔I〕で示さ
れる長鎖活性アミドを混合してリポソームを調製する。In the first method, a liposome is prepared by mixing a long-chain active amide represented by the general formula [I] with a liposome constituent material.
本発明第一の方法に係るリポソームの構成素材としては
ホスファチジルエタノールアミン、ホスファチジルセリ
ンを除く既存のリポソームの製造法において用いられる
脂質が挙げられる。(例えば、卵黄レシチンや大豆レシ
チン等の天然レシチン、ジ/ξルミトイルホスファチジ
ルコリン(DPPC)、 シミリストイルホス7アチ
ジルコリン(1)MPC)、ジステアロイルホス7アテ
ジルコリン(])8PC)、ジオレイルホス7アチジル
コリン(DOPC)、 ジパルミトイルホス7アチジ
ルグリセロール(DPPG)、シミリストイルホスファ
チジン酸(DMPA)等が挙げられる。)
尚、用いられる脂質に一種類でも二穫類以上でもよい。The constituent materials of the liposome according to the first method of the present invention include lipids used in existing liposome manufacturing methods, excluding phosphatidylethanolamine and phosphatidylserine. (For example, natural lecithins such as egg yolk lecithin and soybean lecithin, di/ξ lumitoylphosphatidylcholine (DPPC), cimilistoylphos-7 atidylcholine (1) MPC), distearoylphos-7 atidylcholine (])8PC), dioleylphos-7 atidylcholine (DOPC) ), dipalmitoylphos-7-acylglycerol (DPPG), simyristoylphosphatidic acid (DMPA), and the like. ) The lipids used may be one type or two or more types.
また、コレステロール類等との混合系でもよい。また、
脂質、コレステロール類以外のものを混合してもよい。A mixed system with cholesterol and the like may also be used. Also,
Things other than lipids and cholesterol may be mixed.
本発明第一の方法において、一般式CI)で示される長
鎖活性アミドの全リポソーム構成素材に対するモル比は
、リポソームが構成可能な範囲ならば自由に選択できる
が好ましくは!OS以下、さらに好ましくはJ!チ以下
がよい。In the first method of the present invention, the molar ratio of the long-chain active amide represented by the general formula CI) to the total liposome constituent materials can be freely selected as long as it is within the range that allows liposomes to be constructed, but preferably! Below the OS, more preferably J! Less than 1 is better.
本発明第一の方法に係るリポソーム調製法としてはポル
チックスイング法、超音波法、界面活性剤除去法、逆相
蒸発法CREV法)、エタノール注入法、エーテル注入
法、プレーベシクル法(Pre−Vesicle法)、
フレンチプレス押出法、エクストルージョンCExtr
usion法)、アニーリング法(Annealing
法)、凍結融解法、W10/WエマルジH7法、さらに
8tablePlurilamellar resi
cle法(5PLV法)〔バイオケミストリー(Bio
chemistry)、第2!巻、2Il1頁、lりi
s年〕、等の通常の方法がすべて挙げられる。Liposome preparation methods according to the first method of the present invention include portic swing method, ultrasonic method, surfactant removal method, reverse phase evaporation method (CREV method), ethanol injection method, ether injection method, and pre-vesicle method (Pre- Vesicle method),
French press extrusion method, extrusion CExtr
annealing method), annealing method
method), freeze-thaw method, W10/W emulsion H7 method, and 8table Plurilamellar resi
cle method (5PLV method) [Biochemistry (Bio
chemistry), 2nd! Volume, 2Il1 page, lii
s year], etc., all the usual methods are mentioned.
これらのリポソーム調製法に関しては、Papahad
jopoulsらによる総貌[Ann。For methods of preparing these liposomes, see Papahad
A review by Jopouls et al. [Ann.
Rev−Biophys、Bioeng、、第2巻、4
17頁、1yro年〕、野島、抄本、弁上らによる底置
〔リポソーム、pp、2/−参〇、南江堂(lりrt)
)に記数されている。Rev-Biophys, Bioeng, Volume 2, 4
17 pages, 1 year], Nojima, excerpt, bottom set by Bengami et al. [liposome, pp, 2/-30, Nankodo (lrit)
).
本発明第一の方法、に係るリポソームに内包可#:な化
合物とじては各種薬剤、抗生物質1色素、螢光性物質等
が挙げられる。Compounds that can be encapsulated in the liposomes according to the first method of the present invention include various drugs, antibiotic dyes, fluorescent substances, and the like.
以上のように調製した表面修飾可能7Z Qボソーム分
散液にアミノ基あるいはチオール基tWする基質、また
は基質溶液を加え静置あるいに振とうすることにより基
質をリポソームに固定化した表面修飾リポソームを製造
できる。A substrate having an amino group or a thiol group, or a substrate solution, is added to the surface-modifiable 7Z Q bosome dispersion prepared as described above, and the substrate is immobilized on the liposome by leaving it standing or shaking. Can be manufactured.
本発明第一の方法に係る固定化する基質としてはアミノ
基あるいにチオール基t−有していればよい、好ましく
に、アミノ基含有した基質がよい。The substrate to be immobilized according to the first method of the present invention may have an amino group or a thiol group, preferably a substrate containing an amino group.
これらの基質としては例えばオキシトシン、バンプレシ
ン、甲状腺刺激ホルモン分泌ホルモン(TRH)等の生
理活性はプチド、ホルモン等のはブチド(アミノ酸を含
む)、例えば、IgQ。Examples of these substrates include oxytocin, vanpressin, thyroid-stimulating hormone secreting hormone (TRH), and other physiologically active substances such as butide and hormones such as butide (containing amino acids), such as IgQ.
IgE、IgM等の免疫グロブリン等の抗原、ガン胎児
性抗原(CEA)、膵ガン胎児性抗原(POA)、 α
−7エトプロテインモ7クローナル抗体、免疫グロブリ
ンモノクローナル抗体、牛血清アルブミン(B8A)等
のたんばく質、例えばグルコサミン、ガラクトサミン等
の糖(多St−含む)等が挙けられる。Antigens such as immunoglobulins such as IgE and IgM, carcinoembryonic antigen (CEA), pancreatic carcinoembryonic antigen (POA), α
-7 ethoprotein mo7 clonal antibody, immunoglobulin monoclonal antibody, proteins such as bovine serum albumin (B8A), and sugars (including poly-St) such as glucosamine and galactosamine.
本発明第一〇方法における表面修飾可能なあるいに表面
修飾されたリポソームの精製に通常の方法により行なう
ことができる。例えばセファデックス、セファローズカ
ラムによるゲルろか法、遠心分離法、透析法が挙げられ
る。Purification of surface-modified or surface-modified liposomes in method 10 of the present invention can be carried out by conventional methods. Examples include gel filtration methods using Sephadex and Sepharose columns, centrifugation methods, and dialysis methods.
第二の方法は、本発明第一の方法で述べたアミン基ある
いにチオール基含有した基質と一般式CI)で示される
長鎖、活性アミドを有機溶媒中あるいは水、緩衝液中に
て、混合して長鎖基ヲ有した基質誘導体とする。これを
精製した後にリポソーム構成素材に混合してリポソーム
を調製する。The second method is to use a substrate containing an amine group or a thiol group as described in the first method of the present invention and a long-chain active amide represented by the general formula CI) in an organic solvent, water, or a buffer solution. , are mixed to form a substrate derivative having a long chain group. After this is purified, it is mixed with liposome constituent materials to prepare liposomes.
本発明第二の方法において、リポソーム構成素材として
は、本発明第一の方法で示した他に、ホス7アチジルエ
タノールアミンやホス7アチジルセリン等を用いてもよ
い。本発明第二の方法において長鎖基を臂する基質誘導
体に対するリポソーム構成素材の比にリポソーム構成可
能な範囲で自由に撰択できるが、好ましくは!O−以下
、さらに好ましくは3!チ以下がよい。In the second method of the present invention, as the liposome constituent material, in addition to those shown in the first method of the present invention, phos-7 atidylethanolamine, phos-7 atidyl serine, etc. may be used. In the second method of the present invention, the ratio of the liposome constituent material to the substrate derivative containing the long chain group can be freely selected within the range that allows liposome composition, but preferably! O- or less, more preferably 3! Less than 1 is better.
本発明第二の方法に係るリポソーム調製法、リポソーム
に内包可能な化合物、リポソームに固定化する基質、リ
ポソームの精製に本発明第一の方法と同様である。The liposome preparation method according to the second method of the present invention, the compound that can be encapsulated in the liposome, the substrate to be immobilized in the liposome, and the purification of the liposome are the same as the first method of the present invention.
さらに本発明第二の方法において、リポソーム調製法に
よっては長鎖基を有した基質誘導体を精製することなし
に用いてもよい。また、基質誘導体を含んだ水、緩衝液
? +)ボンーム分散液としてもよい。Furthermore, in the second method of the present invention, a substrate derivative having a long chain group may be used without purification depending on the liposome preparation method. Also, water or buffer containing the substrate derivative? +) It may be used as a bonme dispersion.
本発明で用いる一般式CI)で示される長鎖活性アミド
のR1に疎水性基を示す。R1に一本鎖でも二本鎖でも
よい。−重鎖を有する凡lに直鎖でも分岐でもよく、ま
た飽和でも不飽和でもよい。A hydrophobic group is shown in R1 of the long-chain active amide represented by the general formula CI) used in the present invention. R1 may be single-stranded or double-stranded. - It has a heavy chain and may be linear or branched, and may be saturated or unsaturated.
さらに置換基を有していてもよい。Rtt!疎水性基と
してコレステロール類を有していてもよい。It may further have a substituent. Rtt! It may have cholesterol as a hydrophobic group.
二本鎖t−有する几lとしては、例えば、R5−0−C
H2
(R4、R5は炭素数l−ココまでのアルキル基金示す
、凡4、R5に直鎖でも分岐でもよく、また飽和でも不
飽和でもよい、さらに置換基金有していてもよい。n
u /〜3を示す、キラル炭素に関しては光学活性体で
もラセミ体でもよい、゛)が差げられる。For example, R5-0-C
H2 (R4 and R5 represent an alkyl group having up to 1 carbon atoms, approximately 4, R5 may be linear or branched, saturated or unsaturated, and may have a substituent group.n
Regarding the chiral carbon exhibiting u/~3, it may be an optically active form or a racemic form.
一本鎖を有するR1に、炭素数1以上の直鎖アルキル基
が好ましく、炭素数7−以上の直鎖アルキル基がさらに
好ましい。R1 having a single chain is preferably a straight-chain alkyl group having 1 or more carbon atoms, and more preferably a straight-chain alkyl group having 7 or more carbon atoms.
二本鎖を有するR、とじては、R4、凡5が共に炭素数
1以上の直鎖アルキル基が好ましく、更には炭素数12
以上の直鎖アルキル基が好ましい。For R having a double chain, both R4 and R5 are preferably linear alkyl groups having 1 or more carbon atoms, more preferably 12 carbon atoms.
The above straight chain alkyl groups are preferred.
一般式〔I〕で示される長鎖活性アミドの、R2,83
は有機基(Hl−含む、)を示す。R2,R3は互いに
連結して、環(飽和炭化水素環、飽和へテロ環、芳香環
(ヘテロffiを含む)など)を形成してもよい、さら
に、二重結合を形成してもよい。R2,83 of the long chain active amide represented by general formula [I]
represents an organic group (including Hl-). R2 and R3 may be connected to each other to form a ring (saturated hydrocarbon ring, saturated heterocycle, aromatic ring (including heteroffi), etc.), and may also form a double bond.
R2、R3としては、例えば、H,−CH3、−CH2
CH3,−QH,−COOH,−COOCH3、−CH
2−OH,−CH2−C0OH。R2 and R3 are, for example, H, -CH3, -CH2
CH3, -QH, -COOH, -COOCH3, -CH
2-OH, -CH2-COOH.
Φ Φ
−CH2−COOCH3、−NH3、−N(CH3)3
、Φ
も、Hあるいに一0H1−COOHl−N(CH3)3
、−SO4基を有するものが好ましい。Φ Φ -CH2-COOCH3, -NH3, -N(CH3)3
,Φ is also H or 10H1-COOHl-N(CH3)3
, -SO4 groups are preferred.
X、YはOまたは8を示す。好ましくはX=Y=8であ
る。X and Y represent O or 8. Preferably X=Y=8.
長鎖活性アミドの合成に関しては、特開昭14I−7り
27!号;テトラヘドロン レターズ(Tetrahe
dron Letters)、 第コ l 巻、 t
4!/頁、lりto年;シンセシス(Synthesi
s)、/りtコ年、933頁;マクaモレキュルズ(M
acromolecules)、第一27巻、lり頁、
lりtr年等に記載されている方法を用いて合成できる
。Regarding the synthesis of long-chain active amides, see JP-A-14I-7-27! Issue: Tetrahedron Letters
Dron Letters), Volume 1, t
4! / page, year to year; Synthesis
s), /ritko, 933 pages; Maca Molecules (M
acromolecules), Volume 127, page 1,
It can be synthesized using the method described in Litr et al.
以下に本発明の一般式〔I〕で表わされる長鎖活性アミ
ドの好ましい員体例を示す。しかし、本発明はこれらに
限定されるものでニナい。Preferred examples of the long-chain activated amide represented by the general formula [I] of the present invention are shown below. However, the present invention is not limited to these.
−j
I−タ
以下に本発明の合成例及び実施例を示すが、本発明はこ
れらに限定されるものでにない。Synthesis Examples and Examples of the present invention are shown below, but the present invention is not limited thereto.
合成例1.〈長鎖活性アミドI−/の合成〉(一般式(
1〕においてRIC17H35、R+2=R3=)(%
x=y=s )
ステアリンflに、’#tジクロロメタンjoOdに溶
解し、ジシクロへキシルカルiジイミド(DCC)を≠
、ogMJえ攪拌した。30分後に2=メルカプトーコ
−チアゾリンコ、コy、ジメチルアミノゼ・、す、ジン
(DMAP)0.コ、pt−加えた。−昼夜放置して、
沖過し、p液に水を加え有機階音ぼう硝乾燥した後ジク
ロロメタンを減圧留去した。残留物をシリカゲルクロマ
ト(#!離液ヘキサン/a酸エチルー472 )を経て
ヘキサンによる再結晶全行ない精製して、長鎖活性アミ
ドt−i<一般式(1) KオイテR1= Cl7H3
5、R2”’R3=H%X冨Y=8 ) i 、−gを
得た。Synthesis example 1. <Synthesis of long-chain active amide I-/> (general formula (
1], RIC17H35, R+2=R3=)(%
x=y=s) In stearin fl, dissolve dicyclohexylcari diimide (DCC) in '#t dichloromethane joOd.
, ogMJ was stirred. After 30 minutes, 2 = mercaptoco-thiazolinco, coy, dimethylaminase, su, gin (DMAP) 0. Co, pt- added. -Leave it day and night,
After filtration, water was added to the p-liquid, and after drying, dichloromethane was distilled off under reduced pressure. The residue was purified by silica gel chromatography (#! syneresis hexane/ethyl acetate 472) and recrystallized with hexane to form a long-chain active amide t-i<general formula (1) K-OiteR1=Cl7H3
5, R2'''R3=H%
合成例2.<長鎖活性アミドl−jの合成〉(一般式(
I)においてhx=C13H27、R2=R3=H%X
=Y=O)
ミリスチン酸≠、t9、ジクロロメタン!o。Synthesis example 2. <Synthesis of long-chain active amide l-j> (general formula (
In I) hx=C13H27, R2=R3=H%X
=Y=O) Myristic acid≠, t9, dichloromethane! o.
1、コーオキサゾリドン/−7j9.DCC≠。1. Cooxazolidone/-7j9. DCC≠.
01、DMAPO,2g奮用いて合成例1.と同様にし
て長鎖活性アミドI−j(一般式C1)において几1
=C13H27、R2=B 3=H,X=Y=0)コ、
りgを得た。Synthesis Example 1 using 01, 2 g of DMAPO. Similarly, in the long chain active amide I-j (general formula C1),
=C13H27, R2=B 3=H, X=Y=0),
I got a rig.
合成例3.〈長鎖活性アミドI−tの合成〉CH2
R2−−C−0−CH3(8体)、R3=H1X=Y工
S)
カルボベンゾキシ−!−グルタミン酸−0j9、全テト
ラヒドロフラン300nlに溶解しDCC4C。Synthesis example 3. <Synthesis of long-chain active amide I-t> CH2 R2--C-0-CH3 (8 bodies), R3=H1X=Y-S) Carbobenzoxy-! -Glutamic acid-0j9, dissolved in 300 nl of total tetrahydrofuran, DCC4C.
−Iを力Uえた。次にセチルアミン≠、rp、トリエチ
ルアミン<TEA)コ、/gt加え一昼夜放置した。溶
媒留去後残留物をクロロホルムに溶解し有機層を、水で
洗った後はう硝乾燥をしてクロロホルムを減圧留去した
。シリカゲルクロマト(fg離液 ヘキサン/酢酸エチ
ル=r7a )により精製して、ジアルキルアミド体4
’、J#t−得た。-I got stronger. Next, cetylamine≠, rp, triethylamine <TEA), /gt was added and left overnight. After evaporation of the solvent, the residue was dissolved in chloroform, the organic layer was washed with water, dried with nitrate, and chloroform was distilled off under reduced pressure. It was purified by silica gel chromatography (fg syneresis hexane/ethyl acetate=r7a), and dialkylamide compound 4 was obtained.
', J#t-obtained.
これ全酢酸エチルに溶解しj%パラジウムカーボン/、
09t−用いて加水素分解を行った。(5時間)反応液
に、セライト’を用いて、ろ過し、ろ液の酢酸エチルを
減圧留去してアミン体[11)J。This was dissolved in total ethyl acetate and j% palladium carbon/,
09t- was used for hydrolysis. (5 hours) The reaction solution was filtered through Celite', and the ethyl acetate in the filtrate was distilled off under reduced pressure to obtain the amine compound [11)J.
りを得ゞ・ 8体
次に、グルタル酸無水物/ 、 0111kTHFII
C溶解した。これに、アミン体〔■〕3.4L9、TE
Ao、tgクロロホルム液100ydf滴下した。2時
間後溶媒を減圧留去し、クロロホルムを加え。Next, glutaric anhydride/, 0111kTHFII
C dissolved. In addition to this, amine body [■] 3.4L9, TE
Ao, tg chloroform solution (100 ydf) was added dropwise. After 2 hours, the solvent was distilled off under reduced pressure, and chloroform was added.
有機層を希塩酸で洗い(水層pH=j〜l)有機層をぼ
う硝乾燥して、クロロホルム全減圧留去した。残留物を
ジクロロメタン=00xlに溶解しDCC/、jgを加
えて30分攪拌した。The organic layer was washed with diluted hydrochloric acid (aqueous layer pH=j-l), dried over sulfur and chloroform was completely distilled off under reduced pressure. The residue was dissolved in dichloromethane = 00xl, DCC/Jg was added, and the mixture was stirred for 30 minutes.
≠(R)−メトキシカルボニルーコーメル力ブトーーー
チアゾリy/ 、Oji、DMAPO、/9f加えて、
−晩装置した。反応液をろ過し、ろ液を水で洗い、π機
階音ぼう硝乾燥してジクロロメタンを減圧留去した。残
留物全シリカゲルクロマト(溶離液 ヘキサン/酢酸エ
チル=4/4’)Kて精製して長鎖活性アミドI((一
般式CI)において
I M
8体
C)12
R2=−COCHa CR体)、X=Y=S)2.3g
を得た。≠(R)-Methoxycarbonyl-comel-butot-thiazoliy/, Oji, DMAPO, /9f In addition,
- It was installed in the evening. The reaction solution was filtered, and the filtrate was washed with water and dried over a pycnometer to remove dichloromethane under reduced pressure. The entire residue was purified by silica gel chromatography (eluent: hexane/ethyl acetate = 4/4') to give long-chain active amide I (I M 8-form C) 12 R2=-COCHa CR-form in (general formula CI), X=Y=S)2.3g
I got it.
実施例i、<表面修飾可能なリポソームの製造法〉1)
PPC/j■、長鎖活性アミドl−/(一般式CI)に
おいて、R1= C10H3!i、R2=R3=H%X
=Y =8 ) 2 、 JMfk 1m1(D/ a
a*ルムに溶解した後ロータリーエバポレーターニヨ
リ溶媒留去し薄膜を形成させた。これを減圧で乾燥した
後に、R20、jWLlを加えto 0cの水浴に/分
間静置、ポルテックスミキシングで1分間振とうを交互
に3回行った後プローブ型ンニケーターを用いて超音波
照射を行った。(コjW、3分間)次にセファローズ弘
Bカラムを用いてゲルろかを行い表面修飾可能なリポソ
ーム金得た。(Tc4t10C1平均粒径jj0nm)
実施例2.<表面修飾可能fi IJボンームの内包試
験〉実施例1と同様に分散液金200mM !、(4
)−カルポキンフルオロセイン(j 、 (A )−C
F)pHIr 、!ホウ酸緩衝液を用いて、リポソーム
を調製して、j、(4)−CF内包リすンーム會得た。Example i, <Method for producing surface-modifiable liposomes> 1)
PPC/j ■, long chain active amide l-/ (general formula CI), R1=C10H3! i, R2=R3=H%X
=Y =8) 2, JMfk 1m1(D/a
After dissolving in a*lum, the solvent was distilled off using a rotary evaporator to form a thin film. After drying this under reduced pressure, R20 and jWLl were added, and the mixture was left to stand for 1 minute in a water bath at 0C. After shaking for 1 minute alternately 3 times using portex mixing, ultrasonic irradiation was performed using a probe-type innicator. Ta. (CojW, 3 minutes) Next, gel filtration was performed using a Sepharose Hiro B column to obtain surface-modifiable liposome gold. (Tc4t10C1 average particle size jj0 nm) Example 2. <Encapsulation test of surface-modifiable fi IJ bomb> Same as Example 1, dispersion liquid gold 200mM! ,(4
)-carpoquine fluorescein (j, (A)-C
F) pHIr,! A liposome was prepared using a borate buffer to obtain a molecule containing j,(4)-CF.
(平均粒径j 00 n m )
実施例1〈表面修飾可能なリポソームの製造法とその内
包試験〉
DPPCJOmg、長鎖活性アミド■−3(一般式(I
)においてR1=C13H27、R2=凡3=)1.X
=Y=0 )2Wk、/ ! Ill (r) りo
cr ホルムに溶解し、実施例10方法と同様にして表
面修飾可能なリポソーム(Tc4c/’C1平均粒径コ
λOnm ) t”得た。さらに200mM j 、
(≦)−CF pH7,≠リン酸緩衝液を用いて、同
様にリポソームを調製してj、(4)−CF内包リすン
ーム(平均粒径コ/ On m )’を得た。(Average particle size j 00 nm) Example 1 <Production method of surface-modifiable liposomes and their inclusion test> DPPCJOmg, long-chain active amide ■-3 (general formula (I
), R1=C13H27, R2=about 3=)1. X
=Y=0)2Wk,/! Ill (r) Rio
cr form and obtained surface-modifiable liposomes (Tc4c/'C1 average particle size λOnm) t" in the same manner as in Example 10. Furthermore, 200 mM j,
Liposomes were similarly prepared using (≦)-CF pH 7, ≠ phosphate buffer to obtain (4) -CF-containing membranes (average particle size Co/On m)'.
実施例4.<表面修飾可能なリポソームの製造法とその
内包試験〉
Egg PCJoag、長鎖活性7ミ)−(−rH2
?
R2=−C−OCH3(R体)、X=Y=8)λ■5i
zxtのクロロホルムに溶解して、実施例1の方法と同
様にして表面修飾可能なリポソーム(平均粒径/ 20
n m ) ’に得た。実施例3と同様にして、t、
(4) −CF内包リすンームを得た。Example 4. <Production method of surface-modifiable liposomes and their inclusion test> Egg PCJoag, long chain activity 7mi)-(-rH2? R2=-C-OCH3 (R form), X=Y=8)λ■5i
Surface-modifiable liposomes (average particle size/20
nm)'. In the same manner as in Example 3, t,
(4) - Obtained CF inclusion name.
実施例i〈表面修飾可能なリポソームとその内包試験〉
DPPCJOダ、長鎖活性アミドエータ(一般式CI)
において
R2=H3=H,X=Y=8 )
3〜′t″2jdのクロロホルムに溶解して、実施例1
の方法と同様にして表面修飾可能なリポソーム(平均粒
径/!0nrn)Ir得た。Example I <Surface-modifiable liposome and its encapsulation test> DPPCJOda, long-chain active amide ether (general formula CI)
In Example 1, R2=H3=H,
Ir surface-modifiable liposomes (average particle size/!0nrn) were obtained in the same manner as in the method described above.
実施例3と同様にしてj、(j)−CF内包リポソーム
を得た。In the same manner as in Example 3, a j,(j)-CF-encapsulating liposome was obtained.
実施例6.<ベンジルアミン固定表面飾修すボンームの
製造〉
実施例1.と同様にリン酸緩衝液(pH7,j)を用い
て調製した表面修飾可能なリポソームリン酸緩衝液(p
H7,j)分散液0,4tm(長鎖活性アミドI−/
(一般式CI’JにおいてR1=Cl7H35、′&2
=3s=H,X=Y=iS )、濃度$X10−’M)
ic参X10−2Mベンジルアミンリン酸緩衝液(pH
7,j)a、/mlを加えl−時間、2!0Cで静置し
た。その結果、リボン−ム膜中の長鎖活性アミド(一般
式(1)においてR1=ctyHas、R2=R3=H
,X=Y=8 )の!Osに対してベンジルアミンが固
定化されたベンジルアミン固定表面修飾リポソームラ得
り。Example 6. <Production of benzylamine-fixed surface-decorated bonme> Example 1. Surface-modifiable liposome phosphate buffer (p
H7,j) Dispersion 0.4tm (long chain active amide I-/
(In the general formula CI'J, R1=Cl7H35,'&2
=3s=H,X=Y=iS), concentration $X10-'M)
IC reference X10-2M benzylamine phosphate buffer (pH
7,j)a,/ml was added and allowed to stand at 2!0C for 1 hour. As a result, long-chain active amides in the ribbon membrane (R1=ctyHas, R2=R3=H
,X=Y=8)! Obtaining a benzylamine-immobilized surface-modified liposome in which benzylamine was immobilized on Os.
実施例7.〈ペプチド固定表面修飾リポソームの製造〉
実施例6.と同様にw4製した表面修飾可能なリポソー
ムリン酸緩衝N(pH7−j)分散液0.4!1(長鎖
活性アミドI−/(一般式(1)においてR1=C17
)(as・32 =R3=H,X=Y=87濃度4AX
/−0”−’M)lC4A×IO−2Mk−)’fド(
Gly−8er−β−Ala)リン酸緩衝液(pH7−
1)0.1Wlt加え72時間、コt’cで静置した。Example 7. <Production of peptide-immobilized surface-modified liposomes> Example 6. Surface-modifiable liposome phosphate buffered N (pH 7-j) dispersion 0.4!1 (long-chain active amide I-/(R1=C17 in general formula (1)) prepared in the same manner as W4.
) (as・32 = R3=H, X=Y=87 density 4AX
/-0"-'M)lC4A×IO-2Mk-)'fdo(
Gly-8er-β-Ala) phosphate buffer (pH 7-
1) 0.1 Wlt was added and left standing under a cot for 72 hours.
その結果、リポソーム膜中の長鎖活性アミドI−/、(
一般式(I)において几1 =C17H35、R2=R
3=H1X−Y−81)JtToに対し−Cペプチド(
Gly−8er−β−Ala)が固定化されたペプチド
固定表面修飾リポソームを得た。As a result, long-chain active amide I-/, (
In general formula (I), 几1=C17H35, R2=R
3=H1X-Y-81) JtTo versus -C peptide (
A peptide-immobilized surface-modified liposome on which Gly-8er-β-Ala) was immobilized was obtained.
実施例8.〈たんばく質固定表面修飾リポソームの製造
〉
実施例1.と同様にして、DPPC/ j■、長鎖活性
アミド■−コ(一般式(1)においてR1=cisHa
1%R2=Ra =H,X=Y=8 )/ 、。Example 8. <Production of protein-immobilized surface-modified liposomes> Example 1. Similarly, DPPC/j■, long chain active amide ■-co (R1=cisHa in general formula (1)
1%R2=Ra=H,X=Y=8)/.
■、分散液にPB8溶液を用いて表面修飾可能なIJ
ホソームを得たつこれfO,−μmのミクロボアフィル
ターを用いてエクストノ)−ダーでz oocにおいて
サイジンブレだ。これを超遠心分離機を用いてリポソー
ムを沈降させた。(1万回転、l1分間)
このリポソーム沈査に31のリン酸緩衝液tmえた。そ
のうち、1mにヒト−IgG /■/1PBS浴液1
1會加え、72時間、コj’Cで静置した。これを超遠
心分離機を用いて、PB8溶液で精製して、たんぽ(質
(ヒト−IgG)が固定化されたたんばく質固定表面修
飾リポソームを得た。■IJ that can be surface modified using PB8 solution in the dispersion
To obtain fosomes, a microbore filter of fO,-μm was used to obtain an extonosome and a sizing blur in the zooc. The liposomes were sedimented using an ultracentrifuge. (10,000 revolutions, 1 minute) A 31 m phosphate buffer solution was added to this liposome sediment. Of these, 1 m contains human-IgG/■/1 PBS bath solution 1
The mixture was added once and left to stand in Coj'C for 72 hours. This was purified using a PB8 solution using an ultracentrifuge to obtain a protein-immobilized surface-modified liposome on which human IgG was immobilized.
実施例9.〈ペプチド固定表面修飾リポソームの製造〉
実施例4.と同様に調製した長鎖活性アミドI−j(一
般式(1)において
8体
H2
R2−COCHa (R体)、X=Y=8)を埋め込ん
だ表面修飾可能なリポソーム分散液ldにペプチド(G
ly−8er−β−Ala)水溶液’i/―加え72時
間、コj ’Cで静置した。ゲル濾過によりリポソーム
分画をとりペプチド(Gly−set−β−Ala)が
固定化されたリポソームを得た。Example 9. <Production of peptide-immobilized surface-modified liposomes> Example 4. Peptide ( G
ly-8er-β-Ala) aqueous solution 'i/- was added and allowed to stand at COJ'C for 72 hours. A liposome fraction was collected by gel filtration to obtain a liposome on which a peptide (Gly-set-β-Ala) was immobilized.
実施例10.<糖固定修飾リポソームの製造〉長地らの
方法〔テトラヘドロンレターズ(Tetrahedro
n Lett、)、、第一21巻14/L/頁、lり1
0年〕を用いて、N−テトラデカノイルグルコサミン(
III ) !iり。Example 10. <Production of sugar-fixing modified liposomes> Method of Nagachi et al. [Tetrahedron Letters
n Lett, ), Volume 121, 14/L/page, L1
0 years], N-tetradecanoylglucosamine (
III)! Iri.
13H27
N−テトラデカノイルグルコサミンl■、DPPClj
■ヲメタノール/クロロホルム=l/l溶液j1に溶解
した後ロータリーエバポレーターにより溶媒留去し薄膜
を形成させた。減圧乾燥後にPBS溶液を31加えて、
to 0c水浴に1分間静置、ボルテツクスミキンング
1分間振とりを交互に3回行った後、プローブ型ンニケ
ーターを用いて超音波照射を行った。(21W、10分
間)セファa−ズ参Bを用いたゲルろかによりこれを精
製して、糖(グルコサミン)が固定化された修飾リポソ
ームを得た。13H27 N-tetradecanoylglucosamine l■, DPPClj
(2) After dissolving in methanol/chloroform=l/l solution j1, the solvent was distilled off using a rotary evaporator to form a thin film. After drying under reduced pressure, add 31% of PBS solution,
After standing in a to 0c water bath for 1 minute, vortexing and shaking for 1 minute alternately three times, ultrasonic irradiation was performed using a probe-type innicator. (21W, 10 minutes) This was purified by gel filtration using Sephas A's B to obtain a modified liposome with immobilized sugar (glucosamine).
実施例11.<表面修飾可能なリポソームの加水分解と
アミド形成挙動の観察〉
実施例1.と同様に調製した長鎖活性アミドI−/(一
般式〔I〕において几1 =C17H35、R2=R3
=H,X=Y=8 )を埋め込んだ表面修飾可能なリボ
ソーム0 、4Axlにホウ酸緩衝液(pH//、I=
/、0)0.Id金加えて系中の長鎖活性アミドl−/
の減少yHPLc(Csカラム資生堂裏、CH3CN#
離液ンによ離液跡した。Example 11. <Observation of hydrolysis and amide formation behavior of surface-modifiable liposomes> Example 1. A long-chain active amide I-/(in the general formula [I], 1 = C17H35, R2 = R3
= H,
/, 0) 0. Id gold plus long chain active amide l-/
Decrease in yHPLc (Cs column Shiseido back, CH3CN#
There were syneresis marks due to syneresis.
同様にμ、0x10 Mヘンシルアミンリン酸緩衝
液(pH7,7、I=/、0)0.ldを加えてアミド
形成を調べた。結果全第1図に示す。Similarly μ, 0x10 M hensylamine phosphate buffer (pH 7,7, I=/, 0) 0. ld was added to check for amide formation. The results are shown in Figure 1.
この結果より長鎖活性アミドI−/(一般式(I)にお
いてR1=Cl7H35、a2=R3=H,X=Y=8
)t!IJボンーム系においてpH/Iでほとんど加水
分解は進行しないが、アミンとにpH7゜jにおいても
アミドを形成することを見い出した。This result shows that long-chain active amide I-/(in general formula (I), R1=Cl7H35, a2=R3=H, X=Y=8
)t! It has been found that in the IJ bombe system, hydrolysis hardly progresses at pH/I, but amide is formed with amines even at pH 7°j.
比較例1.<安息香酸活性アミドあるいにエステルの加
水分解速度およびアミド形成速度
の測定〉
表1に示す安息香酸活性アミドあるいにエステル、J、
JJXlo−3Mジオキサン液1.!1と0.1Mリン
酸緩衝液(pH7、≠)J、jlllを混合LHPLC
(ODS力7ム、CHaCN−H2o(O,コlI A
c OH−E t s N )溶離液)により安息
香酸活性アミドあるいにエステルの減少を追跡して加水
分解速度の測定を行った。同様に/3JX10−2M、
グリシンメチルエステル塩酸塩リン酸緩衝液(pH7−
3)J、!−を用いてアミド形成速度を測定した。結果
を表/に示す。Comparative example 1. <Measurement of hydrolysis rate and amide formation rate of benzoic acid activated amide or ester> Benzoic acid activated amide or ester shown in Table 1, J,
JJXlo-3M dioxane liquid 1. ! Mix 1 and 0.1M phosphate buffer (pH 7, ≠) J, JllLHPLC
(ODS force 7m, CHaCN-H2o(O, col IA
The hydrolysis rate was measured by tracking the decrease in benzoic acid active amide or ester using cOH-EtsN) eluent). Similarly /3JX10-2M,
Glycine methyl ester hydrochloride phosphate buffer (pH 7-
3) J,! - was used to measure the amide formation rate. The results are shown in Table/.
この結果より、チアゾリジン−コーチオンを脱離基に持
つ長鎖活性アミドは従来固定化やアミド形成に多用され
るN−ヒドロキシスクシンイミドエステルより水中にお
いて安定であり、さらにアミノ基とは選択的に反応する
ことが認められた・(発明の効果)
以上のように本発明を用いることにより、非常に穏和な
条件において、非常に簡単な操作によってリボンーム表
面に種々の基質を固定化して表面修飾リポソームを製造
することができる。また、本発明で用いられる長鎖活性
アミドは、リポソームへ基質を固定化するためによく用
いられるh−ヒドロキシスクシンイミドエステル(例え
ば5PDP法)と比べ水中での安定性がよく操作性が高
い。These results show that long-chain active amides with thiazolidine-corchion as a leaving group are more stable in water than N-hydroxysuccinimide esters, which are conventionally used for immobilization and amide formation, and are also selectively reactive with amino groups. (Effects of the Invention) As described above, by using the present invention, surface-modified liposomes can be produced by immobilizing various substrates on the surface of the ribbon beam under very mild conditions and with very simple operations. can be manufactured. Furthermore, the long-chain active amide used in the present invention has better stability in water and higher operability than h-hydroxysuccinimide ester (for example, 5PDP method), which is often used to immobilize substrates on liposomes.
第1図はリボンーム膜中に埋め込んだ長鎖活性アミドI
−/ (一般式(1)においてR1=C17H35、
R2=R3=H,X=Y=8 )の!nC/Co=/n
濃度/初濃度を時間に対してプロットしたものである。Figure 1 shows long-chain active amide I embedded in the ribbon membrane membrane.
−/ (In general formula (1), R1=C17H35,
R2=R3=H, X=Y=8)! nC/Co=/n
Concentration/initial concentration is plotted against time.
Claims (3)
ーム形成可能な脂質から構成されることを特徴とする表
面修飾可能なリポソーム。 ▲数式、化学式、表等があります▼〔 I 〕 (R_1は疎水性基を示す。R_2、R_3は有機基(
Hを含む)を示す。R_2、R_3は互いに連結して環
又に二重結合を形成してもよい。X、Yは酸素原子また
硫黄原子を示す。(1) A surface-modifiable liposome characterized by being composed of a compound represented by the general formula [I] below and a liposome-formable lipid. ▲There are mathematical formulas, chemical formulas, tables, etc.▼ [I] (R_1 represents a hydrophobic group. R_2 and R_3 are organic groups (
(including H). R_2 and R_3 may be connected to each other to form a ring or a double bond. X and Y represent an oxygen atom or a sulfur atom.
アミノ基及び/又はチオール基を有する基質を混合する
ことを特徴とする表面修飾されたリポソームの製造方法
。(2) A method for producing a surface-modified liposome, which comprises mixing the surface-modifiable liposome according to claim (1) with a substrate having an amino group and/or a thiol group.
化合物の少なくとも1種とアミノ基及び/又はチオール
基を有する基質を結合させて得られた化合物とリポソー
ム形成可能な脂質を混合することを特徴とする表面修飾
されたリポソームの製造方法。(3) Mixing a compound obtained by binding at least one compound represented by the general formula [I] according to claim (1) with a substrate having an amino group and/or a thiol group and a lipid capable of forming liposomes. A method for producing surface-modified liposomes, characterized by:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2104670A JPH045226A (en) | 1990-04-20 | 1990-04-20 | Surface-modifiable liposomes and methods for producing surface-modified liposomes |
| US07/687,799 US5190822A (en) | 1990-04-20 | 1991-04-19 | Surface-modifiable liposome and process for producing surface-modified liposome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2104670A JPH045226A (en) | 1990-04-20 | 1990-04-20 | Surface-modifiable liposomes and methods for producing surface-modified liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH045226A true JPH045226A (en) | 1992-01-09 |
Family
ID=14386908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2104670A Pending JPH045226A (en) | 1990-04-20 | 1990-04-20 | Surface-modifiable liposomes and methods for producing surface-modified liposomes |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH045226A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042166A1 (en) * | 1996-05-02 | 1997-11-13 | Terumo Kabushiki Kaisha | Amidine derivatives and drug carriers comprising them |
| JP2005162678A (en) * | 2003-12-03 | 2005-06-23 | Konica Minolta Medical & Graphic Inc | Liposomes for liposomes, liposomes and methods for producing them |
| JP2005220034A (en) * | 2004-02-03 | 2005-08-18 | Konica Minolta Medical & Graphic Inc | Method for producing contrast medium for X-ray examination |
| JP2005232054A (en) * | 2004-02-18 | 2005-09-02 | Konica Minolta Medical & Graphic Inc | Method for producing liposome-containing preparation, and liposome-containing preparation |
-
1990
- 1990-04-20 JP JP2104670A patent/JPH045226A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042166A1 (en) * | 1996-05-02 | 1997-11-13 | Terumo Kabushiki Kaisha | Amidine derivatives and drug carriers comprising them |
| US6228391B1 (en) | 1996-05-02 | 2001-05-08 | Terumo Kabushiki Kaisha | Amidine derivatives and drug carriers comprising the same |
| JP2005162678A (en) * | 2003-12-03 | 2005-06-23 | Konica Minolta Medical & Graphic Inc | Liposomes for liposomes, liposomes and methods for producing them |
| JP2005220034A (en) * | 2004-02-03 | 2005-08-18 | Konica Minolta Medical & Graphic Inc | Method for producing contrast medium for X-ray examination |
| JP2005232054A (en) * | 2004-02-18 | 2005-09-02 | Konica Minolta Medical & Graphic Inc | Method for producing liposome-containing preparation, and liposome-containing preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4845090A (en) | Nitroxyl compound and diagnostic media based thereon useful for enhancing NMR imaging | |
| US4275000A (en) | Peptide macromolecular complexes | |
| Vegners et al. | Use of a gel‐forming dipeptide derivative as a carrier for antigen presentation | |
| US4598051A (en) | Liposome conjugates and diagnostic methods therewith | |
| JP4470197B2 (en) | Sterol derivatives, sterol derivative-containing liposomes and methods for loading liposomes with active substances | |
| EP0036277B1 (en) | Covalently bonded liposome-protein-compositions and method of producing them | |
| US4656252A (en) | Amidobiotin compounds useful in a avidin-biotin multiple layering process | |
| WO1986004232A1 (en) | Liposome composition and method | |
| US5190822A (en) | Surface-modifiable liposome and process for producing surface-modified liposome | |
| JPH0482893A (en) | Peptide-derived phospholipid compound and production of polypeptide liposome using the same | |
| CA2458474C (en) | Zwitterionic lipid compound and uses thereof | |
| JPH045226A (en) | Surface-modifiable liposomes and methods for producing surface-modified liposomes | |
| JP2008195757A (en) | Mannose 6-phosphate-polyethylene glycol conjugate | |
| JP4226324B2 (en) | Carboxylic acid type lipid | |
| US4806466A (en) | Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes | |
| JPS6084297A (en) | Novel aminoprine derivative | |
| Fujita et al. | Two-dimensional assembly formation of hydrophobic helical peptides at the air/water interface: fluorescence microscopic study | |
| JPH0499718A (en) | Surface-modifiable liposomes and methods for producing surface-modified liposomes | |
| JPH07242680A (en) | Reactive endoplasmic reticulum, forming agent and functional substance-immobilized endoplasmic reticulum | |
| Konieczny et al. | Bis azo dye liquid crystalline micelles as possible drug carriers in immunotargeting technique | |
| JPH0572915B2 (en) | ||
| JP2601373B2 (en) | Amphiphilic compound and liposome using the same | |
| CN101002942A (en) | PEG type elaioplast nanometer particle medicine | |
| KR100293572B1 (en) | A method for preparation of polymerized liposome by controlling of PH | |
| JP3303481B2 (en) | Reactive endoplasmic reticulum and forming agent |